Xiao-Yan Xu1, Chang-Qing Deng1, Jian Wang1, Xiao-Juan Deng1, Qian Xiao2, Yuan Li3, Qi He1, Wen-Hui Fan1, Feng-Ying Quan1, Yao-Ping Zhu1, Ping Cheng1, Guo-Jun Chen1. 1. a 1 Chongqing Key Laboratory of Neurology, Department of Neurology, The First Affiliated Hospital of Chongqing Medical University , Chongqing , China. 2. b 2 Department of Gerontology, The First Affiliated Hospital of Chongqing Medical University , Chongqing , China. 3. c 3 Department of Geriatrics, Chongqing Mental Health Center , GeLeShan Branch, Chongqing , China.
Abstract
BACKGROUND: A decreased plasma level of soluble form of the receptor for advanced glycation end products (sRAGE) in patients with Alzheimer's disease (AD) has been reported. However, no evidence has shown whether the sRAGE plasma level of AD patients may differentiate from other types of dementia. METHODS: Our study assessed sRAGE concentrations in the following 121 individuals in Chongqing area: 36 patients with AD, 12 with vascular dementia (VaD), 14 with mixed dementia (MD), 24 with other dementia (OD) including Parkinson's disease dementia, frontotemporal dementia, paralytic dementia and 35 cognitively normal controls. The total plasma level of sRAGE was determined using sandwich ELISA method. RESULTS: sRAGE concentration in AD is significantly decreased compared with healthy controls. However, the receiver operating characteristic curve analysis of sRAGE between the AD and the control shows a low diagnostic accuracy. CONCLUSIONS: Our results demonstrate that sRAGE may assist the diagnosis of AD from normal individuals, but cannot differentiate AD from VaD, MD or OD.
BACKGROUND: A decreased plasma level of soluble form of the receptor for advanced glycation end products (sRAGE) in patients with Alzheimer's disease (AD) has been reported. However, no evidence has shown whether the sRAGE plasma level of ADpatients may differentiate from other types of dementia. METHODS: Our study assessed sRAGE concentrations in the following 121 individuals in Chongqing area: 36 patients with AD, 12 with vascular dementia (VaD), 14 with mixed dementia (MD), 24 with other dementia (OD) including Parkinson's disease dementia, frontotemporal dementia, paralytic dementia and 35 cognitively normal controls. The total plasma level of sRAGE was determined using sandwich ELISA method. RESULTS: sRAGE concentration in AD is significantly decreased compared with healthy controls. However, the receiver operating characteristic curve analysis of sRAGE between the AD and the control shows a low diagnostic accuracy. CONCLUSIONS: Our results demonstrate that sRAGE may assist the diagnosis of AD from normal individuals, but cannot differentiate AD from VaD, MD or OD.
Authors: Edwin R Miranda; Vikram S Somal; Jacob T Mey; Brian K Blackburn; Edward Wang; Sarah Farabi; Kristian Karstoft; Ciaran E Fealy; Sangeeta Kashyap; John P Kirwan; Laurie Quinn; Thomas P J Solomon; Jacob M Haus Journal: Am J Physiol Endocrinol Metab Date: 2017-08-15 Impact factor: 4.310
Authors: Kelly N Z Fuller; Edwin R Miranda; John P Thyfault; Jill K Morris; Jacob M Haus Journal: Mediators Inflamm Date: 2018-02-22 Impact factor: 4.711